Replies to post #896 on Aurinia Pharmaceuticals Inc (AUPH)

[Lunacy_John Galt]

I finally got a chance to listen to the Q&A section of the March 2nd presentation. It sounds like they will most likely change the primary endpoint of the Phase 3 study to 52 weeks, and make 24 weeks a Secondary endpoint. I think that would be a very wise decision as the P-value improved drastically from 24 to 48 weeks.